More than half of people diagnosed with generalized anxiety disorder or depression respond poorly to first-line treatments, and no new treatments for anxiety have been approved in nearly two decades. Promising clinical trials now suggest this may finally be changing, but only if New York’s regulatory system modernizes to allow timely patient access to emerging therapies.
Several investigational therapies targeting serotonin and glutamate pathways have shown rapid reductions in anxiety symptoms within hours, rather than the weeks it takes for medications currently on the market. Other compounds have demonstrated significant improvement for patients with treatment-resistant depression, including individuals who have not responded to multiple rounds of SSRIs or SNRIs. These advances are supported by multiple phases of clinical research.
The challenge is that when the U.S. Food and Drug Administration approves a new clinically tested mental-health treatment and the Drug Enforcement Administration reschedules it, additional regulatory hurdles await at the state level. New York has no timely system for aligning its controlled-substance schedule with federal action. With no set timeline, potentially life-changing therapies can sit in bureaucratic limbo long after rigorous scientific trials have confirmed their safety and effectiveness.
New York should modernize its process by requiring the state to update its controlled-substance schedule within a clear, reasonable timeframe after federal action. This would not weaken oversight but would ensure New Yorkers are not left waiting behind unnecessary red tape. The state supports more than 5,000 biotech and research companies and commits billions of dollars to growing the sector, yet its policies have not kept pace with its institutions’ innovations.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.lohud.com/story/opinion/2026/01/27/ny-mental-health-care-innovation-opinion/88365063007/